RxDoctor Payments Data

Sandrivette Johnson

Nurse Practitioner · Raleigh, NCNPI 1740201458

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $369,415 of the $572,550 with a category attached, or 64.5%. 37 manufacturers reported payments, led by AbbVie at 25.5% of the total. Among nurse practitioner clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$572,550in general payments, 2019–2025

Across 1,896 payments — averaging $301.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$146K
  • Johnson & Johnson$91K
  • Sanofi$46K
  • Lilly USA, LLC$40K
  • Arcutis Biotherapeutics, Inc.$40K
  • E.r. Squibb & Sons, L.L.C.$31K
  • plus $179K from 31 others

What the payments were for

  • Consulting fees$105,22118%
  • Speaking & faculty fees$369,41565%
  • Travel & lodging$62,51711%
  • Food & beverage$34,9156%
  • Education$3660%
  • Gifts$1170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572,550 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$141,575
Medicare patients
578
Services billed
2,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib28$190,939
AdbryTralokinumab-Ldrm17$64,647
Clobetasol Propionate111$4,379
Doxycycline Hyclate90$2,710
Betamethasone Dipropionate49$2,373
Tacrolimus18$1,810
Fluorouracil15$1,774
Triamcinolone Acetonide104$1,517
Dutasteride52$1,298
Metronidazole21$1,224
Ketoconazole78$1,109
Tretinoin12$1,074
Fluocinolone Acetonide20$1,006
Spironolactone45$839
ValacyclovirValacyclovir Hcl12$515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$146,202$190,93928 claims
LEO Pharma Inc.Adbry$25,759$64,64717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →